<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02713815</url>
  </required_header>
  <id_info>
    <org_study_id>Mzhao-004</org_study_id>
    <nct_id>NCT02713815</nct_id>
  </id_info>
  <brief_title>Novel Intervention for Amphetamine-type Stimulants Addiction</brief_title>
  <official_title>The Repetitive Transcranial Magnetic Stimulation (rTMS) for Amphetamine-type Stimulants Addiction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Mental Health Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Yunnan Institute For Drug Abuse</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai Mental Health Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The repetitive transcranial magnetic stimulation (rTMS) will be used to treat
      amphetamine-type stimulant (ATS) addiction.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Glutamate and GABA deficits in prefrontal cortex play a vital role in ATS addiction and
      relapse, and proposed repetitive transcranial magnetic stimulation (rTMS) as a novel
      interventions. Focused on evaluating Glutamate/GABA functions in prefrontal cortex and
      functional connectivity with deep brain regions, neuropsychological tests, biochemical tests,
      magnetic resonance spectroscopy (MRS) and functional MRI will be used to investigate the
      neurobiological mechanism of ATS addiction and relapse. These methods will also be used to
      evaluate the efficacy of the novel intervention and investigate the mechanisms. The study
      will be very helpful to develop novel interventions in clinical practice and decrease
      ATS-related harm for both the patients and their families.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2016</start_date>
  <completion_date type="Actual">July 2019</completion_date>
  <primary_completion_date type="Actual">July 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline Craving for ATS assessed by Visual Analog Scales (VAS) at 1 month</measure>
    <time_frame>Baseline and 1 month</time_frame>
    <description>evaluate all participants' craving for ATS by Visual Analog Scales (VAS)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants who relapse</measure>
    <time_frame>1 month</time_frame>
    <description>Follow up with patients after discharge, evaluate number of participants who relapse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depression status assessed by Patient Health Questionnaire-9(PHQ-9)</measure>
    <time_frame>1 month</time_frame>
    <description>evaluate all participants' depression status by Patient Health Questionnaire-9(PHQ-9)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anxiety status assessed by Generalized Anxiety Disorder Screener (GAD-7)</measure>
    <time_frame>1 month</time_frame>
    <description>evaluate all participants' anxiety status by Generalized Anxiety Disorder Screener (GAD-7)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive function assessed by Cogstate Battery</measure>
    <time_frame>1 month</time_frame>
    <description>evaluate all participants' cognition by Cogstate Battery Chinese version</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional connectivity assessed by MRI</measure>
    <time_frame>1 month</time_frame>
    <description>evaluate all participants' functional connectivity in the brain by MRI</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Amphetamine Addiction</condition>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>sham repetitive transcranial magnetic stimulation (rTMS) of the left frontal lobe dorsal lateral effect on ATS dependent induced cognitive dysfunction and other symptoms.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>rTMS group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Use randomized, prospective pseudo stimulus controlled clinical trial design, evaluation of repetitive transcranial magnetic stimulation of the left frontal lobe dorsal lateral effect on ATS dependent induced cognitive dysfunction and other symptoms.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>repetitive transcranial magnetic stimulation (rTMS)</intervention_name>
    <description>Stimulate the dorsomedial prefrontal cortex for 4 weeks by Theta-burst stimulation (TBS), once a day</description>
    <arm_group_label>rTMS group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>sham repetitive transcranial magnetic stimulation (rTMS)</intervention_name>
    <description>Stimulate the dorsomedial prefrontal cortex for 4 weeks by sham Theta-burst stimulation (TBS), once a day</description>
    <arm_group_label>control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  In accordance with the Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5)
             for methamphetamine (MA) use disorders

          -  Dextromanual

        Exclusion Criteria:

          -  Have a disease that affect cognitive function such as history of head injury,
             cerebrovascular disease, epilepsy, etc

          -  Have cognitive-promoting drugs in the last 6 months

          -  Other substance abuse or dependence in recent five years (except nicotine)

          -  Mental impairment, Intelligence Quotient (IQ) &lt; 70

          -  Mental disorders

          -  Physical disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhao Min, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Mental Health Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Shanghai Gaojing Rehabilitation Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>201900</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>March 7, 2016</study_first_submitted>
  <study_first_submitted_qc>March 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 21, 2016</study_first_posted>
  <last_update_submitted>November 30, 2019</last_update_submitted>
  <last_update_submitted_qc>November 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 3, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Amphetamine-type stimulants</keyword>
  <keyword>prefrontal-striatal circuits</keyword>
  <keyword>rTMS</keyword>
  <keyword>Glutamate/GABA</keyword>
  <keyword>motivational and cognitive intervention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amphetamine-Related Disorders</mesh_term>
    <mesh_term>Behavior, Addictive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

